References
- Potts JR, Verma S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. World J Gastroenterol. 2011;17:2070–2075.
- Czaja AJ. Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci. 2013;58:897–914.
- Takahashi H, Zeniya M. Acute presentation of autoimmune hepatitis: does it exist? A published work review. Hepatol Res. 2011;41:498–504.
- Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.
- Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.
- Liberal R, Longhi MS, Mieli-Vergani G, et al. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2011;25:653–664.
- Czaja AJ. Targeting apoptosis in autoimmune hepatitis. Dig Dis Sci. 2014;59:2890–2904.
- Yamada S, Ogata I, Hirata K, et al. Intravascular coagulation in the development of massive hepatic necrosis induced by Corynebacterium parvum and endotoxin in rats. Scand J Gastroenterol. 1989;24:293–298.
- Arai M, Mochida S, Ohno A, et al. Sinusoidal endothelial cell damage by activated macrophages in rat liver necrosis. Gastroenterology. 1993;104:1466–1471.
- Mochida S, Ohno A, Arai M, et al. Role of adhesion between activated macrophages and endothelial cells in the development of two types of massive hepatic necrosis in rats. J Gastroenterol Hepatol. 1995;10:S38–S42.
- Mochida S, Arai M, Ohno A, et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology. 1999;29:1532–1540.
- Kato J, Okamoto T, Motoyama H, et al. Interferon-gamma-mediated tissue factor expression contributes to T-cell-mediated hepatitis through induction of hypercoagulation in mice. Hepatology. 2013;57:362–372.
- Kotoh K, Ueda A, Tanaka M, et al. A high prevalence of extreme hyperferritinemia in acute hepatitis patients. Hepat Med. 2009;1:1–8.
- Srungaram P, Rule JA, Yuan HJ, et al. Plasma osteopontin in acute liver failure. Cytokine. 2015;73:270–276.
- Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–675.
- Urata K, Kawasaki S, Matsunami H, et al. Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 1995;21:1317–1321.
- Kotoh K, Enjoji M, Kato M, et al. A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: a retrospective study. Comp Hepatol. 2008;7:6.
- Kotoh K, Kato M, Kohjima M, et al. Lactate dehydrogenase production in hepatocytes is increased at an early stage of acute liver failure. Exp Ther Med. 2011;2:195–199.
- Kotoh K, Kato M, Kohjima M, et al. A new treatment strategy for acute liver failure. World J Hepatol. 2010;2:395–400.
- Hiraoka A, Horiike N, Akbar SM, et al. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol. 2005;40:52–56.
- Tajiri T, Tate G, Kunimura T, et al. Osteopontin expression in proliferated bile ductules: the correlation with liver damage in fulminant hepatitis. Dig Dis Sci. 2005;50:188–195.
- Moller HJ, Gronbaek H, Schiodt FV, et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol. 2007;47:671–676.
- Possamai LA, Thursz MR, Wendon JA, et al. Modulation of monocyte/macrophage function: a therapeutic strategy in the treatment of acute liver failure. J Hepatol. 2014;61:439–445.
- Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010;196:369–405.
- Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.
- vanDeWater L, Carr JM, Aronson D, et al. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease. Blood. 1986;67:1468–1473.
- Tanaka M, Ohkita T. Analysis of fibrinogen degradation product in severe liver disorders by immunoblotting. Tohoku J Exp Med. 1987;153:179–187.